Editorial comment

Lai and colleagues present a nicely written retrospective analysis evaluating the relationship between prescription of abiraterone and enzalutamide to Medicare patients and pharmaceutical manufacturer payments to urologists and medical oncologists. During the years 2014- –2017 promotional payments were made to over one quarter of medical oncologists and one half of urologists who care for Medicare patients. Furthermore, increased payment levels were associated with increased prescription of abiraterone or enzalutamide.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research